BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Authors » Tamra Sami

Articles by Tamra Sami

Profitability in sight for Admedus with Vascucel approval

Oct. 18, 2016
By Tamra Sami

Profitability is in sight for Admedus with Vascucel approval

Oct. 18, 2016
By Tamra Sami
PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months. The FDA cleared Vascucel for marketing on Oct. 17, and the company expects to launch the collagen scaffold for repairing vascular tissue in November.
Read More

Australian government makes VC pot sweeter for biotech investments

Oct. 12, 2016
By Tamra Sami
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
Read More

Australian Government makes VC pot sweeter for lifescience investments

Oct. 6, 2016
By Tamra Sami

Australian government makes VC pot sweeter for biotech investments

Oct. 6, 2016
By Tamra Sami
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
Read More

Proposed R&D tax incentive could hurt Australia’s small firms

Oct. 5, 2016
By Tamra Sami
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
Read More

Australia's R&D tax incentive could hurt small med-tech and biotech companies

Oct. 3, 2016
By Tamra Sami

Proposed R&D tax incentive could hurt Australia’s small firms

Oct. 3, 2016
By Tamra Sami
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
Read More

Australia gears up to reform drug, device regulations, speed access to therapies

Sep. 21, 2016
By Tamra Sami
PERTH, Australia – The pharma and medical device industry praised the Australian government on new reforms announced late last week that increase the pathways for marketing approval for drugs and devices and reduce regulatory red tape and redundancies.
Read More

Australia gears up to reform drug, device regulations, speed access to therapies

Sep. 19, 2016
By Tamra Sami
Previous 1 2 … 226 227 228 229 230 231 232 233 234 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing